Highlights From TD Cowen's 2026 US Corporate Access Day With REGN Management

Research evidence excerpt

Highlights From TD Cowen's 2026 US Corporate Access Day With REGN Management

Biotechnology

Regeneron Pharmaceuticals

TD SECURITIES (USA) LLC QUICK TAKE: CONFERENCE TAKEAWAY

June 24, 2026

Price: $618.03 (06/23/2026) Highlights From TD Cowen's 2026

Price Target: $960.00 US Corporate Access Day With REGN

Management

BUY (1)

ESG SCORE: 58/100

Tyler Van Buren THE TD COWEN INSIGHT

646 562 1343

At TD Cowen's 2026 US Corporate Access Day, we hosted REGN for investor meetings.

tyler.vanburen@tdsecurities.com

Management highlighted strong Eylea HD demand, improving durability from dosing flexibility

Nicholas Lorusso and RVO, and limited long-term biosim risk. Dupixent remains a high growth product with

646 562 1390 potential LOE extension upside. The pipeline remains underappreciated with C5, obesity,

nick.lorusso@tdsecurities.com

Factor XI, and Libtayo combos in late-stage dev.

Sam Rollenhagen

212 468 7785 Below, please find the main highlights from our meeting. We discuss each of the highlights in

samuel.rollenhagen@tdsecurities.com detail in the PDF.

Greg W. Torres, Ph.D. Dupixent Growth, LOE, Life Cycle Extension, And SNY Collaboration

646 562 1351

gregory.wiessner@tdsecurities.com (1) Broad-Based Execution Keeps Dupixent On A Strong Growth Trajectory

Ikenna Okafor, Ph.D. (2) 2031 Remains The Base Case For LOE, Though Multiple Paths Could Extend The Runway

646 562 1395

ikenna.okafor@tdsecurities.com (3) Long-Acting Cytokine Approaches Could Create A Meaningful Franchise Bridge Beyond

Dupixent

Key Data

Symbol NASDAQ: REGN (4) Management Strives To Reach A Global 50-50 Profit Share With Sanofi That Better Reflects

Market Cap $63.7B Today's Reality

Click here for the full company update from (5) The Payor Disclosure Lawsuit Reflects A Broader Push For Transparency And Control